Retinoic acid receptor alpha (RAralpha) Mutations in Human Leukemia

Leukemia & Lymphoma
Antonio ParradoR A Padua

Abstract

The retinoic acid receptor alpha (RARalpha) plays a central role in the biology of the myeloid cellular compartment. Chromosomal translocations involving the RARalpha locus probably represent the malignant initiating events in acute promyelocytic leukemia (APL). Recent studies that identify novel interactions between RARalpha and the nuclear receptor co-activators and co-repressors, new functions of the oncogenic RARalpha fusion proteins and their catabolism in retinoic acid-induced differentiation, and the availability of new transgenic mice models have provided important insights into our understanding of the mechanisms by which mutant forms of RARalpha can be implicated in the development of leukemia. Novel alterations of the RARalpha gene identified in hematopoietic malignant disorders other than APL, such as myelodysplastic syndromes, non-APL acute myeloid leukemias and B-chronic lymphocytic leukemias, suggest that disruption of the RARalpha gene might predispose to myeloid and lymphoid disorders.

References

Mar 1, 1992·Genes & Development·D J MangelsdorfR M Evans
Jun 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M AlcalayP G Pelicci
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·P LeroyP Chambon
Dec 17, 1987·Nature·V GiguereR M Evans
Apr 28, 1988·Nature·N BrandA Dejean
Jul 3, 1995·Proceedings of the National Academy of Sciences of the United States of America·P ShockettD G Schatz
Aug 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·S Tsai, S J Collins
Jan 1, 1996·Current Opinion in Oncology·P Fenaux, C Chomienne
Dec 1, 1996·Journal of Human Lactation : Official Journal of International Lactation Consultant Association·D G Revell
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·D BrownJ M Bishop
May 13, 1997·Proceedings of the National Academy of Sciences of the United States of America·L Z HeP P Pandolfi
Aug 19, 1997·Proceedings of the National Academy of Sciences of the United States of America·S H HongM L Privalsky
Sep 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·M H KokenA Zelent
Oct 10, 1997·Cell·R L Johnson, C J Tabin

❮ Previous
Next ❯

Citations

Jan 20, 2005·Molecular and Cellular Biology·Karin B KindleDavid M Heery
Feb 11, 2004·Proceedings of the National Academy of Sciences of the United States of America·Antonio ParradoM Rocío Alvarez-López
Oct 30, 2004·Leukemia & Lymphoma·Suman KambhampatiLeonidas C Platanias
Jun 1, 2007·Biochemical and Biophysical Research Communications·Maria Victoria BernardoAntonio Parrado
Jun 18, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Shao-Jun Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.